Cargando…

Vitamins A, E and D and cancer risk in BRCA1 carriers

Detalles Bibliográficos
Autores principales:	Kąklewski, K, Gackowski, D, Durda, K, Huzarski, T, Gronwald, J, Dębniak, T, Tołłoczko, A, Ashuryk, O, Jakubowska, A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Meeting Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3395397/ http://dx.doi.org/10.1186/1897-4287-10-S3-A10

Ejemplares similares

Folic acid and cancer risk in BRCA1 carriers
por: Durda, Katarzyna, et al.
Publicado: (2012)

Serum concentration of iron as predictor of cancer risk among BRCA1 mutation carriers
por: Sukiennicki, Grzegorz, et al.
Publicado: (2012)

Serum concentration of selected macro- and microelements and their correlation with the risk of breast and ovarian cancer among BRCA1 mutation carriers
por: Muszyńska, Magdalena, et al.
Publicado: (2012)

Selenium and genotypes as marker of risk in BRCA1 mutation carriers
por: Jaworska, K, et al.
Publicado: (2012)

Prospective observation of breast/ovarian cancer risk in BRCA1 carriers depending on serum selenium level optimized with diet
por: Lubiński, J, et al.
Publicado: (2012)

Selenium and the risk of cancer in BRCA1 carriers
por: Lubinski, J, et al.
Publicado: (2011)

Neoadjuvant chemotherapy with Cisplatin in BRCA1 mutation carriers – results of treatment
por: Byrski, T, et al.
Publicado: (2012)

Why choose the treatment with cisplatin for BRCA1 breast cancers patients?
por: Byrski, T, et al.
Publicado: (2012)

BRCA1 founder mutations and ovarian cancer in Belarus
por: Savanevich, A, et al.
Publicado: (2015)

Folic acid and breast cancer risk
por: Durda, Katarzyna, et al.
Publicado: (2012)

Rapid test for detection of high risk of breast cancer
por: Durda, K, et al.
Publicado: (2012)

Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
por: Byrski, T, et al.
Publicado: (2011)

Identification of new genes associated with breast and ovarian cancer risk. Advances of BCAC, CIMBA and OCAC
por: Jakubowska, A, et al.
Publicado: (2011)

Cisplatin in breast cancer treatment in BRCA1 carriers
por: Gronwald, Jacek, et al.
Publicado: (2012)

The risk of breast cancer in women with a CHEK2 mutation
por: Cybulski, Cezary, et al.
Publicado: (2012)

CHEK2 mutations as markers for high risk of breast cancer
por: Cybulski, Cezary, et al.
Publicado: (2012)

Iron and breast cancer risk
por: Sukiennicki, Grzegorz, et al.
Publicado: (2012)

Selenium (Se) and the risk of breast, ovarian and prostate cancers
por: Jaworska, Katarzyna, et al.
Publicado: (2012)

Copper as diagnostic marker of cancers
por: Muszyńska, Magdalena, et al.
Publicado: (2015)

Magnesium as a diagnostic marker of cancer
por: Marciniak, Wojciech, et al.
Publicado: (2015)

Selenium as diagnostic marker of cancers
por: Jaworska-Bieniek, Katarzyna, et al.
Publicado: (2015)

Zinc as diagnostic marker of cancers
por: Kaczmarek, Katarzyna, et al.
Publicado: (2015)

Iron as diagnostic marker of cancer
por: Sukiennicki, Grzegorz, et al.
Publicado: (2015)

Zinc and breast cancer risk
por: Kaczmarek, Katarzyna, et al.
Publicado: (2012)

Selenium (Se) and breast cancer risk
por: Jaworska - Bieniek, Katarzyna, et al.
Publicado: (2012)

Combined iPLEX and TaqMan assays to screen for 45 common mutations in Lynch syndrome and FAP patients
por: Dymerska, D, et al.
Publicado: (2011)

Selenium and cancer risk in CHEK2 mutation carriers
por: Gupta, Satish, et al.
Publicado: (2012)

Meeting abstracts from the Annual Conference on Hereditary Cancers 2016: Szczecin, Poland. 14-15 September 2016
por: Cybulski, C., et al.
Publicado: (2017)

Pathological complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients
por: Byrski, Tomasz, et al.
Publicado: (2015)

Association of tamoxifen use and reduced risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers
por: Phillips, KA, et al.
Publicado: (2012)

Impact of BRCA1 mutation on survival after early onset breast cancer
por: Huzarski, T, et al.
Publicado: (2012)

Identification of patients at high risk of negative psychological consequences associated with BRCA1 mutation
por: Ertmański, S, et al.
Publicado: (2012)

Blood Arsenic Levels as a Marker of Breast Cancer Risk among BRCA1 Carriers
por: Marciniak, Wojciech, et al.
Publicado: (2021)

Ovarian cancer risk in Polish BRCA1 mutation carriers is not associated with the prohibitin 3' untranslated region polymorphism
por: Jakubowska, Anna, et al.
Publicado: (2008)

BRCA1 and BRCA2 mutations in ovarian cancer patients from Belarus: update
por: Savanevich, Alena, et al.
Publicado: (2021)

Association of recurrent mutations in BRCA1, BRCA2, RAD51C, PALB2, and CHEK2 with the risk of borderline ovarian tumor
por: Ogrodniczak, Alicja, et al.
Publicado: (2022)

Constitutional genomic instability of 9p23-24 in BRCA2 mutation carriers
por: Savelyeva, L, et al.
Publicado: (2001)

Microelements as risk factors for cancer of the lung and larynx
por: Jaworska-Bieniek, Katrzyna, et al.
Publicado: (2012)

Selenium and the risk of cancer of the lung and larynx. A case-control study from a region with low selenium
por: Jaworska, Katrzyna, et al.
Publicado: (2012)

P53 mutations in breast and ovarian carcinomas from BRCA1 and 2 mutation carriers and noncarriers
por: Sensi, E, et al.
Publicado: (2000)

Cannot write session to /tmp/vufind_sessions/sess_31n652073ar1m832ufcrra6foa